Since its inception in 1996, the company has developed a wide range of CRO and CMO services that include clinical studies and comprise bioequivalence/bioavailability studies, pharmacokinetic profiles, drug-drug interactions, adhesion performance, pain assessment studies, taste assessment for oral suspensions, and blanching (VCA) studies, among others. 3S Pharma’s technology portfolio extends beyond traditional methods, encompassing advanced systems for 3D coding of samples, ICP-MS techniques, and robotic automation, complementing LCMS/ MS techniques and ligand binding assays.
The company’s commitment to innovation is not limited to technology but extends to the creative utilization of tools during clinical studies. For example, thermal photography is used for assessing the adhesion performance of transdermal delivery systems (TDS), facilitating highly accurate and automated data processing. Similarly, 3S Pharma’s injectable products are administered using ultrasound control (colour Doppler technology) to eliminate the risk of accidental injection into a vessel.
3S Pharma’s offerings have a customer-oriented approach that emphasizes the safety of subjects, attention to detail, and a good balance between price and quality. From the initial design of a study to the rigorous implementation of safety measures, the company ensures the well-being of the participants. This involves adhering to meticulously evaluated study protocols, with outlined inclusion and exclusion criteria, without deviation to minimize risk for subjects. It also uses sentinel cohorts as a safety measure that has proven instrumental in maintaining a high level of subject safety throughout the studies.
“We are now actively conducting early-phase clinical trials, including first-in-human studies like single dose ascending studies (SAD), multiple dose ascending studies (MAD), and other Phase 1/1b and Phase 2 (2a and 2b) studies such as drug-drug interaction, drug-food interaction, gender pharmacokinetic, etc,” says Simona Rizea Savu, Managing Director of 3S Pharma.
3S Pharma also offers long-term confinement facilities for certain studies, providing a controlled environment that optimizes subject safety and compliance. It has clinical centers in Romania and Moldavia, strategically chosen to provide access to a diverse pool of volunteers.
The fully dedicated, privately owned clinical research facility in Romania has a capacity of 74 beds, capable of offering long confinement periods. In addition to its private facility, 3S Pharma has collaborative associations with public hospitals in Romania and Moldavia, dedicated to clinical trials if specific patient groups are required. These centers offer a wealth of potential study participants and employ highly skilled doctors and nurses dedicated to the safety and wellbeing of subjects.
To further enhance its commitment to safety and innovation, 3S Pharma conducts annual training programs for its teams, including Clinical Research Associates (CRA), Clinical Investigators, and analytical team. Participation in conferences and scientific events also contributes to the team’s continuous growth and knowledge enrichment for handling the unique challenges of each clinical trial.
We are now actively conducting early-phase clinical trials, including first-inhuman studies like SAD, MAD, and other Phase 1/1b and Phase 2 (2a/2b) studies
As 3S Pharma continues to grow and evolve, it aims to strengthen its collaboration with specialists and practitioners in the field who have practical experience with the products. Increasing the level of information prior to the clinical study designs also ensures that each study is grounded in the latest scientific knowledge.
With a track record of successful studies, a professional team, and a commitment to adhering to protocols, 3S Pharma is well-positioned to meet the evolving needs of the pharmaceutical industry. As the company continues to forge ahead in clinical research, its unwavering commitment to safety and innovation sets them apart as a trusted partner for drug development.
